Silence Therapeutics (SLN) Depreciation & Amortization (CF) (2020 - 2025)
Silence Therapeutics' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $65000.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) fell 14.47% to $65000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $300000.0, a 32.11% decrease, with the full-year FY2025 number at $300000.0, down 10.71% from a year prior.
- Depreciation & Amortization (CF) hit $65000.0 in Q4 2025 for Silence Therapeutics, down from $81000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for SLN hit a ceiling of $169607.3 in Q1 2021 and a floor of $65000.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $123661.6 across 5 years, with a median of $139017.1 in 2024.
- Biggest five-year swings in Depreciation & Amortization (CF): plummeted 63.9% in 2021 and later soared 91.7% in 2022.
- Tracing SLN's Depreciation & Amortization (CF) over 5 years: stood at $86272.7 in 2021, then soared by 91.7% to $165382.9 in 2022, then decreased by 15.95% to $139009.0 in 2023, then tumbled by 45.33% to $76000.0 in 2024, then fell by 14.47% to $65000.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for SLN at $65000.0 in Q4 2025, $81000.0 in Q3 2025, and $81000.0 in Q2 2025.